CD28 and vasculitis: In this respect, the use of Valacyclovir as anti-CMV treatment in patients with Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis was shown not only to suppress CMV reactivation but was also associated with a reduction of the CD4+CD28− T-cell frequency.